The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.

Daniel Cantillon, MD, explained why the positive performance of Abbott's Aveir dual-chamber leadless pacemaker could lead to considerable improvements in patient care. 

Change is on the horizon for cath labs all over the world as more and more interventional cardiologists are starting to use coronary CT angiography to plan and guide PCI procedures. Patients, physicians, catheterization labs and healthcare systems all stand to gain from this growing trend.

The Heart Rhythm Society released a new expert consensus statement on the management of remote device clinics for implantable EP devices.

Results from a pivotal clinical trial presented as a late-breaker at Heart Rhythm 2023 indicate that a new leadless pacemaker technology can deliver cardiac resynchronization therapy in patients who were not able to be treated with conventional CRT and epicardial leads.

The use of left bundle branch area pacing (LBBAP) is growing in electrophysiology implanted devices. Two late-breaking studies at Heart Rhythm 2023 highlight the success of LBBAP as an alternative to the standard of care using biventricular pacing.

The newly approved device is powered by Bluetooth technology and available with a three- or six-year battery.

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris.